APP and Alzheimer disease: In the amyloid precursor protein (APP) transgenic modelof AD, treatment with pioglitazone reduced the plaque burden by affecting theproduction, clearance, and homeostasis of Aβ in the CNS [42].A clinical trial involving 500AD patients showed significantimprovement in cognition following treatment with rosiglitazone for 6 months,suggesting its use in the treatment of AD [43].